CCTG BL13 a randomized phase II trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer (NCT03768570) Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Kassouf, Wassim
  • Crabb, Simon J
  • Duran, Ignacio
  • Brundage, Michael Donald
  • Reaume, M Neil
  • Dragomir, Alice
  • Wyatt, Alexander William
  • Badillo, Francisco Emilio Vera
  • Lukka, Himu
  • Niazi, Tamim
  • Souhami, Luis
  • Sridhar, Srikala S
  • Griffiths, Gareth Owen
  • Howell, Doris
  • Richardson, Harriet
  • Djurfeldt, Marina
  • Ding, Keyue
  • Parulekar, Wendy R

publication date

  • June 1, 2022